Budesonide inhibits interleukin-32 expression in a rat model of chronic obstructive pulmonary disease

REFERENCES

• Coiso MG, Saetta M, Agusti A: Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360:2445–2454.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J, Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176: 532–555.
   PubMed Web of Science ®Google Scholar
• Hogg JC, Timens W: The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol Mech Dis. 2009;4: 435–459.
   PubMed Web of Science ®Google Scholar
• Wright JL, Coiso M, Churg A: Animal models of chonic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2008;295:L1–L15.
   PubMed Web of Science ®Google Scholar
• Szefler SJ: Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol. 1999;104:S175–S181.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock IM: Glucocoticoid resistance in inflammatory diseases. Lancet. 2009;373:1905–1917.
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH Investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA: The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26.
   PubMed Web of Science ®Google Scholar
• Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, Turato G, Lokar-Oliani K, Papi A, Zuin R, Sfriso P, Balestro E, Dinarello CA, Saetta M: IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178:894–901.
   PubMed Web of Science ®Google Scholar
• Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA: Interleukin-32: a cytokine and inducer of TNFα. Immunity. 2005;22:131–142.
   PubMed Web of Science ®Google Scholar
• Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA, Kim SH: IL-32 synergizes with nucleotide oligomerization domain (NOD)1 and NOD2 ligands for IL-1 beta and IL-6 production through a caspase1-dependent mechanism. Proc Natl Acad Sci USA. 2005;102:16309–16314.
   PubMed Web of Science ®Google Scholar
• Meyer N, Zimmermann M, Bürgler S, Bassin C, Woehrl S, Moritz K, Rhyner C, Indermitte P, Schmid-Grendelmeier P, Akdis M, Menz G, Akdis CA: IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol. 2010;125: 858–865.
   PubMed Web of Science ®Google Scholar
• Kempuraj D, Conti P, Vasiadi M, Alysandratos KD, Tagen M, Kalogeromitros D, Kourelis T, Gregoriou S, Makris M, Stavrianeas NG, Theoharides TC: IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. Eur J Dermatol. 2010;20:865–867.
   PubMed Web of Science ®Google Scholar
• Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S, Izuhara K: Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol. 2006;18:233–240.
   PubMed Web of Science ®Google Scholar
• Choi JD, Bae SY, Hong JW, Azam T, Dinarella CA, Her E, Choi WS, Kim BK, Lee CK, Yoon DY, Kim SJ, Kim SH: Identification of the most active interleukin-32 isoform. Immunol. 2008;126:535–542.
   PubMed Web of Science ®Google Scholar
• Heinhuis B, Koenders MI, van Riel PL, van de Loo FA, Dinarella CA, Netea MG, van den Berg WB, Joosten LAB: Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies and inflammatory cascade. Ann Rheum Dis. 2011;70:660–667.
   PubMed Web of Science ®Google Scholar
• Ko NY, Mun SH, Lee SH, Kim JW, Kim DY, Kim HS, Her E, Kim SH, Won HS, Shin HS, Kim HS, Kim YM, Choi WS: Interleukin-32α production is regulated by MyD88-dependent and independent pathways in IL-1β-stimulated human alveolar epithelial cells. Immunobiol. 2011;216:32–40.
   PubMed Web of Science ®Google Scholar
• Mabilleau G, Sabokbar A: Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. Plos One. 2009;4:e4171-e.
   Google Scholar
• Nishida A, Andoh A, Inatomi O, Fujiyama Y: Interleukin-32 expresssion in the pancreas. J Biol Chem. 2009;284:17868–17876.
   PubMed Web of Science ®Google Scholar
• Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB: IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA. 2006;103:3298–3303.
   PubMed Web of Science ®Google Scholar
• Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y, Andoh A: Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol. 2007;149:480–486.
   PubMed Web of Science ®Google Scholar
• Jeong HJ, Shin SY, Oh HA, Kim MH, Cho JS, Kim HM: IL-32 up-regulation is associated with inflammatory cytokine production in allergic rhinitis. J Pathol. 2011;224:553–563.
   PubMed Web of Science ®Google Scholar
• Xu L, Cai B, Zhu Y: Pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease and therapeutic effects of glucorticoids and N-acetylcysterin in rats. Chin Med J. 2004;117:1611–1619.
   PubMed Web of Science ®Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E: Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease-a systematic review and meta-analysis. JAMA. 2008;300:2407–2416.
   PubMed Web of Science ®Google Scholar
• Centanni S, Marco FD: Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2005;6:2525–2534.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T: Effectiveness of fluticasone propionate and salmeterol combination delivered via diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1084–1091.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353:1819–1823.
   PubMed Web of Science ®Google Scholar
• Sin DD, Tashkin D, Zhang X, Radner F, Sjöbring U, Thorén A, Calveley PMA, Renard S: Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet. 2009;374:712–719.
   PubMed Web of Science ®Google Scholar
• Barnes PJ: Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mole Biol. 2010;120:76–85.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Ito K, Adcock IM: Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet. 2004;363:731–733.
   PubMed Web of Science ®Google Scholar
• Donnelly R, Seale P: Clinical pharmacokinetics of inhaled budesonide. Clin Pharmacokinet. 2001;40:427–440.
   PubMed Web of Science ®Google Scholar